A final safety evaluation report released regarding SHINE Medical Technology LLC’s application for a license to operate a medical isotope production facility in Janesville, Wisconsin.

The report concludes there are no safety aspects that would preclude issuing the license for operation of the facility.

The staff finalized the Supplemental Environmental Impact Statement regarding the SHINE application on Jan. 31, 2023. The agency will consider both documents in deciding whether to issue the license.

SHINE filed the application on July 17, 2019, seeking the license to operate the facility, currently under construction in Janesville.

The facility would create molybdenum-99, which subsequently produces technetium-99m, an isotope used in over 30 different diagnostic medical imaging procedures. Information concerning the operating license review, with proprietary details removed, is available on the NRC website.

Schneider Bold

The facility would consist of an irradiation facility (IF) and radioisotope production facility (RPF) for the irradiation and processing of special nuclear material to produce medical radioisotopes, such as molybdenum-99.

In turn, the IF would consist of eight subcritical operating assemblies (or irradiation units (IUs)), which would each be licensed as utilization facilities.

The RPF would consist of hot cell structures and systems, where the irradiated material is processed to separate medical isotopes and where the resulting material is packaged for shipment to customers

Click here for more on the safety report.

Pin It on Pinterest

Share This